Table 3. Recent Patents on the Treatment of Allergic Conjunctivitis.

Patent No.	Publication Name	Description	Ref.
US20100087397	Use of lipid-conjugates in the treatment of conjunctivitis	Lipid-conjugates to inhibit PLA2 enzyme activity control the production of inflammatory mediators and modulators Have membrane stabilizing effects	[63]
WO2009045054	A composition for treatment of conjunctivitis comprising chlorogenic acid and derivatives thereof	Chlorogenic acid or derivative thereof exhibiting anti-inflammatory effects comparable to steroidal drugs have less side effects and provide synergistic action when used in combination with known anti-inflammatory agents	[61]
WO2008035922	A composition comprising glucosamine and derivatives thereof and a method for treatment of conjunctivitis using the same	Glucosamine and derivatives thereof exhibiting anti-inflammatory effects comparable to steroidal drugs have less side effects and provide synergistic action when used in combination with known anti-inflammatory agents	[64]
US20080306163	Agent for treatment of allergic eye disease	3-Anilino-2-cycloalkenonne derivatives for the treatment of allergic conjunctivitis, vernal conjunctivitis and vernal catarrh by having PDE IV inhibitory activity increase intracellular cAMP activity that suppress the activation of the inflammatory cells and provide anti-inflammatory activity	[62]
US20080009476	Treating conjunctivitis by topically administering an epinastine solution to the conjunctiva	Topically administered aqueous solution of epinastine inhibits the influx of neutrophils and tosinophils in to the tissue of ocular conjunctiva and nasal mucous membrane	[65]
WO2009089401	Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same	Novel compositions that bind to TLRs and coreceptors and inhibit the production of cytokines and inflammatory mediators.	[66]
WO2009067081	Pyrimidine derivatives for the treatment of asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis B, hepatitis C, HIV, HPV, bacterial infections and dermatosis	Invention provides pyrimidine derivatives that act on TLR7 receptor and provide immune-modulating properties in the treatment of viral or allergic diseases and cancers	[67]
US20090324507	RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions	Interfering RNA which acts by silencing spleen tyrosine kinase (SyK) and blocks a cascade of events related to mast cell degranulation and prevents the release of histamine and other pro-inflammatory mediators	[68]
US20090274631	RNAi-mediated inhibition of histamine receptor h1-related conditions	Interfering RNA that attenuates the expression of histamine receptor H1 mRNA	[69]
US20090182035	Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis	Pharmaceutical composition containing effective amount of olopatadine and cilomilast for topical administration in the treatment of allergic conjunctivitis and allergic rhinitis	[70]
US20100120741	Heterocyclic inhibitors of histamine receptors for the treatment of disease	Novel heterocyclic compounds are synthesized which have antagonistic effect specifically towards histamine type-1 (H1R) and/or type-4 (H4R) receptors	[71]
US20100081646	Bicyclic heteroaryl inhibitors of PDE4	Bicyclic heteroaryl compounds are provided, which have PDE4 selective effect and have less adverse effects in comparison to other PDE4 inhibitors Regulate the production of cytokines and increase the cAMP levels at the target site	[72]
US20100063047	Aminopyrimidine inhibitors of histamine receptors for the treatment of disease	Novel compounds and pharmaceutical composition having antihistamine effect on H1 and/or H4 receptors are provided for the treatment of histamine-receptor mediated diseases	[73]
US20090324691	Methods and ophthalmic devices used in the treatment of ocular allergies	Provides method for preparing polymerized ophthalmic device with or without minimum effective amount of anti-allergic agent	[74]
US20080051385	Ocular allergy treatments	Method for preventing and treating ocular allergic conditions by applying effective amount of alcaftadine topically Invention provides new therapy that is effective in the treatment of allergic symptoms such as ocular redness, chemosis and eyelid swelling and have longer duration of action	[75]
US7687539	Method of treating ocular allergy	Method of treating allergic conjunctivitis by the use of 5,6,7-trihydroxyheptanoic acid and its analogs alone or in combination with histamine receptor inhibitior and/or a mast cell degranulation inhibitor	[76]
US20100022470	Method for treating allergic diseases	Use of Dendrobii Herba polysaccharides for the treatment of allergic diseases including allergic conjunctivitis via oral administration Polysaccharides used in the present invention increase the number of T regulatory cells in the intestinal lamina propria site that suppress the activation of immune system	[77]